|
1
|
Breuer S, Maimon O, Appelbaum L, et al:
TL-118-anti-angiogenic treatment in pancreatic cancer: a case
report. Med Oncol. 30:5852013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Von Hoff DD, Ervin T, Arena FP, et al:
Increased survival in pancreatic cancer with nab-paclitaxel plus
gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zagouri F, Sergentanis TN, Chrysikos D, et
al: Molecularly targeted therapies in metastatic pancreatic cancer:
a systematic review. Pancreas. 42:760–773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shahrokni A and Saif MW: Metastatic
pancreatic cancer: The dilemma of quality vs. quantity of life.
JOP. 14:391–394. 2013.PubMed/NCBI
|
|
6
|
Rodriguez MA, DeJesus YA, Cheng L, Buzdar
A and Burke TW: Factors related to end-of-life (EOL) chemotherapy
in solid tumor (ST) patients. J Clin Oncol. 31:abstract 9538.
2013.
|
|
7
|
Burke T, DeJesus Y, Cheng L, Buzdar A and
MA R: Pattern of chemotherapy use at end-of-life (EOL) in patients
with solid tumors (ST). J Clin Oncol. 31:abstract 9539. 2013.
|
|
8
|
Romanus D, Kindler HL, Archer L, et al:
Does health-related quality of life improve for advanced pancreatic
cancer patients who respond to gemcitabine? Analysis of a
randomized phase III trial of the cancer and leukemia group B. J
Pain Symptom Manage. 43:205–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li D, Morris JS, Liu J, Hassan MM, Day RS,
Bondy ML and Abbruzzese JL: Body mass index and risk, age of onset
and survival in patients with pancreatic cancer. JAMA.
301:2553–2562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greer JA, Pirl WF, Jackson VA, et al:
Effect of early palliative care on chemotherapy use and end-of-life
care in patients with metastatic non-small-cell lung cancer. J Clin
Oncol. 30:394–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Zhang L and Li Y: Inhibition of
cancer cell proliferation by color modulation: A pilot study. Ann
Oncol. 24 (Suppl 9):ix832013. View Article : Google Scholar
|
|
12
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging handbook. AJCC Cancer
Staging Manual. 7th. Springer; New York: pp. 63–79. 2010
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, et al: New response evaluation criteria in
solid tumours: Revised RECIST guideline (version 1.1). Eur J
Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neoptolemos JP, Stocken DD, Bassi C, et
al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs
gemcitabine following pancreatic cancer resection: a randomized
controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hartwig W, Werner J, Jäger D, et al:
Improvement of surgical results for pancreatic cancer. Lancet
Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Helmut Oettle SP, Peter Neuhaus, Klaus
Gellert, et al: Adjuvant chemotherapy with gemcitabine vs
observation in patients undergoing curative: intent resection of
pancreatic cancer - a randomized controlled trial. JAMA.
297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neoptolemos JP, Stocken DD, Tudur Smith C,
et al: Adjuvant 5-fluorouracil and folinic acid vs observation for
pancreatic cancer: composite data from the ESPAC-1 and -3(v1)
trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oettle H, Neuhaus P, Hochhaus A, et al:
Adjuvant chemotherapy with gemcitabine and long-term outcomes among
patients with resected pancreatic cancer: the CONKO-001 randomized
trial. JAMA. 310:1473–1481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ueno H, Kosuge T, Matsuyama Y, et al: A
randomised phase III trial comparing gemcitabine with surgery-only
in patients with resected pancreatic cancer: Japanese study group
of adjuvant therapy for pancreatic cancer. Br J Cancer.
101:908–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niu L, Chen J, He L, Liao M, Yuan Y, Zeng
J, Li J, Zuo J and Xu K: Combination treatment with comprehensive
cryoablation and immunotherapy in metastatic pancreatic cancer.
Pancreas. 21:1143–1149. 2013. View Article : Google Scholar
|
|
21
|
Epstein AS, Abou-Alfa GK, Shamseddine A,
Al-Olayan A, Ang C, Naghy M, Lowery MA and O'Reilly EM:
Communication and palliative care in a 64-year-old man with
pancreatic adenocarcinoma. Gastrointest Cancer Res. 5:130–134.
2012.PubMed/NCBI
|
|
22
|
Panagiotarakou M, Gupta A, Syrigos K and
Saif MW: Use of supportive care for symptom management in
pancreatic cancer: application of clinical research to patient
care. JOP. 13:342–344. 2012.PubMed/NCBI
|
|
23
|
Paul E and Kenneth P Olive: Pancreatic
cancer: why is it so hard to treat. Ther Adv Gastroenterol.
6:321–337. 2013. View Article : Google Scholar
|
|
24
|
Temel JS, Greer JA, Muzikansky A,
Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD,
Jacobsen J, Pirl WF, Billings JA and Lynch TJ: Early palliative
care for patients with metastatic non-small-cell lung cancer. N
Engl J Med. 363:733–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, et al: CTCAE v3.0: Development of a comprehensive grading
system for the adverse effects of cancer treatment. Semin Radiat
Oncol. 13:176–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
